Multimodal MRI-derived phenotypes in preclinical Alzheimer’s Disease: results from the EPAD cohort
Luigi Lorenzini1, Silvia Ingala1, Alle Meije Wink1, Joost PA Kuijer 1, Viktor Wottschel 1, Carole H Sudre2,3,4,5, Sven Haller6,7, José Luis Molinuevo 8,9,10,11, Juan Domingo Gispert 8,10,11,12, David M Cash3, David L Thomas 13, Sjoerd B Vos 4,13, Prados Ferran14,15,16, Jan Petr17, Robin Wolz18, Alessandro Palombit18, Adam J Schwarz 19, Gael Chételat 20, Pierre Payoux 21,22, Carol Di Perri23, Cyril Pernet 23, Giovanni Frisoni24,25, Nick C Fox 3, Craig Ritchie26, Joanna Wardlaw 23,27, Adam Waldman23,28, Frederik Barkhof1,29, and Henk JMM Mutsaerts 1,30
1Dept. of Radiology and Nuclear Medicine, Amsterdam University Medical Centre, Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, The Netherlands, Amsterdam, Netherlands, 2MRC unit for Lifelong Health and Ageing at UCL, London, UK, London, United Kingdom, 3Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK, London, United Kingdom, 4Centre for Medical Image Computing, University College London, London, UK, London, United Kingdom, 5School of Biomedical Engineering & Imaging Sciences, King’s College London, UK, London, United Kingdom, 6CIRD Centre d’Imagerie Rive Droite, Geneva, Switzerland, Geneva, Switzerland, 7Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, 8Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, Barcelona, Spain, 9CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain, Madrid, Spain, 10IMIM (Hospital del Mar Medical Research Institute), Barcelona Spain, Barcelona, Spain, 11Universitat Pompeu Fabra, Barcelona, Spain, Barcelona, Spain, 12CIBER Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain, Madrid, Spain, 13Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology London, UK, London, United Kingdom, 14Nuclear Magnetic Resonance Research Unit, Queen Square Multiple Sclerosis Centre, University College London Institute of Neurology, London, United Kingdom, London, United Kingdom, 15Department of Medical Physics and Biomedical Engineering, Centre for Medical Image Computing, University College London, London, United Kingdom, London, United Kingdom, 16e-Health Centre, Open University of Catalonia, Barcelona, Spain, Barcelona, United Kingdom, 17Helmholtz‐Zentrum Dresden‐Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany, Dresden, Germany, 18IXICO, London, UK, London, United Kingdom, 19Takeda Pharmaceuticals Ltd., Cambridge, MA, USA, Cambridge, ME, United States, 20Université de Normandie, Unicaen, Inserm, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", institut Blood-and-Brain @ Caen-Normandie, Cyceron, 14000 Caen, France, Caen, France, 21Department of Nuclear Medicine, Toulouse CHU, Purpan University Hospital, Toulouse, France, Toulouse, France, 22Toulouse NeuroImaging Center, University of Toulouse, INSERM, UPS, Toulouse, France, Toulouse, France, 23Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK, Edinburgh, Scotland, 24Laboratory Alzheimer’s Neuroimaging & Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, Brescia, Italy, 25University Hospitals and University of Geneva, Geneva, Switzerland, Geneva, Switzerland, 26Centre for Dementia Prevention, The University of Edinburgh, Scotland, UK, Edinburgh, Scotland, 27UK Dementia Research Institute at Edinburgh, University of Edinburgh, UK, Edinburgh, Scotland, 28Department of Medicine, Imperial College London, London, UK, London, United Kingdom, 29Institute of Neurology and Healthcare Engineering, University College London, London, UK, London, United Kingdom, 30Ghent Institute for Functional and Metabolic Imaging (GIfMI), Ghent University, Ghent, Belgium, Ghent, Belgium
Image-derived phenotypes (IDPs) from multimodal MRI sequences constitute an important resource that allows the characterization of brain alterations in the early stages of Alzheimer diseases and other neurodegenerative conditions. Here, we showed the computation of multimodal IDPs from the European Prevention of Alzheimer Dementia (EPAD) cohort and assessed their relationship with non-imaging markers of neurodegeneration. We demonstrated the clinical relevance of IDPs to uncover early brain alteration in AD by showing expected association with non-imaging data.
This abstract and the presentation materials are available to members only;
a login is required.